Key Drivers
- Debt-Free Balance Sheet
- Strong Cash Generation
- Premium Valuation
AIAI Summary
IRMD's exceptional cash generation, debt-free balance sheet, and high margins make it operationally resilient, but at ~47–50x earnings the stock remains vulnerable unless revenue growth rebounds meaningfully from 0.5% and gross margins stabilize—wait for clear top-line reacceleration before underwriting its premium valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Debt-Free Balance Sheet
- •Strong Cash Generation
- •Premium Valuation
IRMD offers strong liquidity, debt-free operations, high profitability, and solid cash generation, but its premium valuation and recent margin pressure warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Declining trend
- •Oversold momentum
- •Critical support
IRMD remains bearish after a 5.3% decline last month, with oversold conditions supporting a possible bounce only if $81.87 holds, while a reclaim of $84.40 is needed to improve momentum.
Price fell from $87.87 to $82.12 last month
Sentiment & News
Key News Insights:
- •High institutional ownership
- •Valuation concerns persist
- •Fund stake reduction
IRMD remains highly institutionally owned with a strong GF Score, but its overvaluation, recent share weakness, and Algert Global's reduced stake warrant caution.
Near-term sentiment may stay pressured unless IRMD's earnings growth justifies its premium valuation
Similar Companies in Healthcare
Other companies in the same sector with AI ratings